Pharmacokinetics of a hematoregulatory peptide (SK and F 107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy

Pharmaceutical Research

Volumn 17, Issue 4, 2000, Pages 385-390

  Zia Amirhosseini, Parnian ^a   Harris, Robert Z ^a   Cowley, Hugh C ^a   Valle, Juan W ^b   Citerone, David R ^a   Boppana, Venkata K ^a   Scarffe, Howard ^b   Watson, Philip ^a   Davis, Charles B ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Cytokines; Hematoregulatory; Peptide; Pharmacokinetics; SK and F 107647

Indexed keywords

5 OXO L PROLYL L ALPHA GLUTAMYL L ALPHA ASPARTYL N (5 AMINO L CARBOXYPENTYL) 8 OXO N [N[N(5 OXO L PROLYL) L ALPHA GLUTAMYL] L ALPHA ASPARTYL] L 2,7,8 TRIAMINO OCTANOYL LYSINE; ANTIANEMIC AGENT; GLASPIMOD; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; RADIOIMMUNOASSAY;

EID: 0034120740     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007512617139     Document Type: Article

References (11)

1. 1. J. M. Vose and J. O. Armitage. Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 13:1023-1035 (1995).
2. 2. W. P. Steward. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet. 342:153-157 (1993).
3. 3. D. R. Brocks, M. I. Freed, D. E. Martin, T. S. Sellers, N. Mehdi, D. R. Citerone, V. Boppana, B. Levitt, B. E. Davies, J. Nemunaitis, and D. K. Jorkasky. Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharm. Res. 13:794-797 (1996).
4. 4. J. Nemunaitis, D. E. Martin, D. L. Willis, M. I. Freed, B. Levitt, D. A. Richards, J. V. Cox, G. T. Kimmel, W. J. Hyman, and D. K. Jorkasky. SK&F 107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies. A phase I trial. Am. J. Clin. Oncol. 21:189-194 (1998).
5. 5. P. L. DeMarsh, S. K. Sucoloski, C. L. Frey, P. K. Bhatnagar, Y. Koltin, P. Actor, and S. R. Petteway. Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice. Immunopharmacology. 27:199-206 (1994).
6. 6. P. L. DeMarsh, G. I. Wells, T. F. Lewandowski, C. L. Frey, P. K. Bhatnagar, and E. J. R. Ostovic. Treatment of experimental gram-negative and gram-positive bacterial sepsis with the hematoregulatory peptide SK&F 107647. J. Infect. Dis. 173:203-211 (1996).
7. 7. L. M. Pelus, A. G. King, H. E. Broxmeyer, P. L. DeMarsh, S. R. Petteway, and P. K. Bhatnagar. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide. Exp. Hematol. 22:239-247 (1994).
8. 8. D. W. Cockcroft and M. H. Gault. Prediction of creatinine clearance from serum creatinine. Nephron. 16:31-41 (1976).
9. 9. R. Rabkin and D. C. Dahl. Renal Uptake and Disposal of Proteins and Peptides. In K. L. Audus and T. J. Raub (eds.), Biological Barriers to Protein Delivery, New York, Plenum Press, 1993, pp. 299-338.
10. 10. T. Maack, C. H. Park, and M. J. F. Gamaro. Renal filtration, transport, and metabolism of proteins. In D. W. Seldin and G. Giesbisch (eds.), The kidney, physiology and pathophysiology, 2nd edition, New York, Marcel Dekker, 1992, pp. 3005-3038.
11. 11. J. Mordenti, S. A. Chen, J. A. Moore, B. L. Ferraiolo, and J. D. Green. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 8:1351-1359 (1991).